https://www.clinicalobserver.com/research/sacituzumab-tirumotecan-plus-pembrolizumab-improves-pfs-in-pd-l1-negative-nsclcClinical Observeren2026-10-25T18:29:17.844ZSacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1-negative NSCLChttps://www.clinicalobserver.com/public-health/nigeria-reports-first-bundibugyo-ebola-case-as-global-outbreak-tops-9-700Clinical Observeren2026-10-25T18:13:00.427ZNigeria Reports First Bundibugyo Ebola Case as Global Outbreak Tops 9,700https://www.clinicalobserver.com/biotech/tarlatamab-plus-durvalumab-cut-death-risk-58-in-first-line-small-cell-lungClinical Observeren2026-10-25T12:59:25.972ZTarlatamab plus durvalumab cut death risk 58% in first-line small cell lung cancerhttps://www.clinicalobserver.com/public-health/uganda-imposes-21-day-quarantine-on-citizens-returning-from-drcClinical Observeren2026-10-25T12:25:43.939ZUganda imposes 21-day quarantine on citizens returning from DRChttps://www.clinicalobserver.com/public-health/three-die-in-suspected-hantavirus-outbreak-on-atlantic-cruise-shipClinical Observeren2026-10-24T21:16:15.915ZThree die in suspected hantavirus outbreak on Atlantic cruise shiphttps://www.clinicalobserver.com/research/first-ebola-vaccine-trial-in-dr-congo-begins-in-buniaClinical Observeren2026-10-24T15:59:21.800ZFirst Ebola vaccine trial in DR Congo begins in Buniahttps://www.clinicalobserver.com/public-health/kenya-searches-for-missing-ugandan-ebola-contact-as-cases-rise-to-nineClinical Observeren2026-10-24T07:04:16.018ZKenya Searches for Missing Ugandan Ebola Contact as Cases Rise to Ninehttps://www.clinicalobserver.com/public-health/swiss-national-is-first-ebola-bundibugyo-case-in-nigeriaClinical Observeren2026-10-24T02:03:21.676ZSwiss national is first Ebola Bundibugyo case in Nigeriahttps://www.clinicalobserver.com/public-health/kenya-reports-second-ebola-death-with-no-community-spreadClinical Observeren2026-10-24T01:34:58.711ZKenya reports second Ebola death with no community spreadhttps://www.clinicalobserver.com/biotech/merck-and-moderna-report-phase-3-cancer-vaccine-data-early-after-leakClinical Observeren2026-10-23T23:29:43.801ZMerck and Moderna report phase 3 cancer vaccine data early after leakhttps://www.clinicalobserver.com/public-health/nigeria-confirms-first-ebola-case-in-more-than-a-decadeClinical Observeren2026-10-23T23:19:46.058ZNigeria confirms first Ebola case in more than a decadehttps://www.clinicalobserver.com/research/mrna-melanoma-vaccine-plus-keytruda-cut-recurrence-risk-by-42-in-phase-3Clinical Observeren2026-10-23T21:44:41.373ZmRNA melanoma vaccine plus Keytruda cut recurrence risk by 42% in phase 3https://www.clinicalobserver.com/biotech/brepocitinib-meets-primary-endpoint-in-two-phase-3-uveitis-trialsClinical Observeren2026-10-23T21:29:30.677ZBrepocitinib meets primary endpoint in two phase 3 uveitis trialshttps://www.clinicalobserver.com/biotech/izalontamab-brengitecan-cuts-progression-risk-by-59-in-hr-her2-breast-cancerClinical Observeren2026-10-23T20:59:24.574ZIzalontamab brengitecan cuts progression risk by 59% in HR+/HER2- breast cancerhttps://www.clinicalobserver.com/hospitals/mass-general-brigham-cuts-staff-and-halves-home-hospitalClinical Observeren2026-10-23T20:32:27.409ZMass General Brigham cuts staff and halves Home Hospital